JP2010525063A - ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 - Google Patents

ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 Download PDF

Info

Publication number
JP2010525063A
JP2010525063A JP2010506270A JP2010506270A JP2010525063A JP 2010525063 A JP2010525063 A JP 2010525063A JP 2010506270 A JP2010506270 A JP 2010506270A JP 2010506270 A JP2010506270 A JP 2010506270A JP 2010525063 A JP2010525063 A JP 2010525063A
Authority
JP
Japan
Prior art keywords
conjugated compound
virus
compound according
subject
phosphonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010506270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525063A5 (https=
Inventor
ペインター，ジョージ・アール
Original Assignee
キメリクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キメリクス，インコーポレイテッド filed Critical キメリクス，インコーポレイテッド
Publication of JP2010525063A publication Critical patent/JP2010525063A/ja
Publication of JP2010525063A5 publication Critical patent/JP2010525063A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010506270A 2007-04-27 2008-04-25 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 Withdrawn JP2010525063A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91453207P 2007-04-27 2007-04-27
PCT/US2008/005322 WO2008133966A1 (en) 2007-04-27 2008-04-25 Methods of reducing nephrotoxicity in subjects administered with nucleoside

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014233457A Division JP2015063538A (ja) 2007-04-27 2014-11-18 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法

Publications (2)

Publication Number Publication Date
JP2010525063A true JP2010525063A (ja) 2010-07-22
JP2010525063A5 JP2010525063A5 (https=) 2013-05-23

Family

ID=39523817

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010506270A Withdrawn JP2010525063A (ja) 2007-04-27 2008-04-25 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
JP2014233457A Pending JP2015063538A (ja) 2007-04-27 2014-11-18 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014233457A Pending JP2015063538A (ja) 2007-04-27 2014-11-18 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法

Country Status (9)

Country Link
US (2) US20120010170A1 (https=)
EP (1) EP2155257B1 (https=)
JP (2) JP2010525063A (https=)
CN (2) CN101678122A (https=)
AU (1) AU2008246195B2 (https=)
CA (1) CA2685285A1 (https=)
ES (1) ES2609095T3 (https=)
MX (1) MX2009011573A (https=)
WO (1) WO2008133966A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519570A (ja) * 2016-06-28 2019-07-11 キメリックス インコーポレイテッド ブリンシドフォビルの製剤

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
ES2572631T3 (es) 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2770282A1 (en) * 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
CN102665729A (zh) * 2009-10-30 2012-09-12 奇默里克斯公司 用于治疗病毒相关性疾病的方法
CA2779473C (en) * 2009-10-30 2016-08-16 Chimerix, Inc. Methods of treating viral associated diseases
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
AU2015201895B2 (en) * 2010-08-31 2016-11-17 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
WO2012031045A2 (en) * 2010-08-31 2012-03-08 Chimerix, Inc. Phosphonate ester derivatives and methods of synthesis thereof
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP3578563B1 (en) 2011-12-22 2021-04-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
EP2869823A4 (en) * 2012-07-03 2016-03-16 Chimerix Inc METHOD FOR THE TREATMENT OF RETROVIRUS INFECTIONS AND RELATED DOSING PLANS
SG10201800188SA (en) 2013-03-15 2018-02-27 Univ California Acyclic nucleoside phosphonate diesters
US8962829B1 (en) 2013-11-15 2015-02-24 Chimerix, Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
CN111808136B (zh) 2014-09-15 2024-06-11 加利福尼亚大学董事会 核苷酸类似物
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018156879A1 (en) * 2017-02-23 2018-08-30 Chimerix, Inc. Treatment of adenovirus with brincidofovir
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500352A (ja) * 1999-12-03 2004-01-08 ザ　レジェンツ　オブ　ザ　ユニバーシティー　オブ　カリフォルニア　サン　ディエゴ ホスホネート化合物
JP2005508945A (ja) * 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500352A (ja) * 1999-12-03 2004-01-08 ザ　レジェンツ　オブ　ザ　ユニバーシティー　オブ　カリフォルニア　サン　ディエゴ ホスホネート化合物
JP2005508945A (ja) * 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN5010008980; ＢＩＤＡＮＳＥＴ　Ｄ．　Ｊ．: ＴＨＥ　ＪＯＵＲＮＡＬ　ＯＦ　ＩＮＦＥＣＴＩＯＵＳ　ＤＩＳＥＡＳＥＳ Ｖ１９０　Ｎ３, 20040801, Ｐ４９９-５０３ *
JPN5010008982; ＰＡＩＮＴＥＲ　Ｇ　Ｒ: ＴＲＥＮＤＳ　ＩＮ　ＢＩＯＴＥＣＨＮＯＬＯＧＹ Ｖ２２　Ｎ８, 20040801, Ｐ４２３-４２７, ＥＬＳＥＶＩＥＲ　ＰＵＢＬＩＣＡＴＩＯＮＳ *
JPN5010008985; ＤＡＬ　ＰＯＺＺＯ　ＦＡＤＩＡＮＡ: ＡＮＴＩＶＩＲＡＬ　ＲＥＳＥＡＲＣＨ Ｖ７５　Ｎ１, 20070417, Ｐ５２-５７, ＥＬＳＥＶＩＥＲ　ＳＣＩＥＮＣＥ　ＢＶ *
JPN5010008987; ＣＩＥＳＬＡ　Ｓ．　Ｌ．: ＡＮＴＩＶＩＲＡＬ　ＲＥＳＥＡＲＣＨ Ｖ５９　Ｎ３, 200308, Ｐ１６３-１７１ *
JPN5010008990; ＪＯＳＥＰＨＳＯＮ　Ｍ．　Ａ．: ＴＲＡＮＳＰＬＡＮＴ　ＩＮＦＥＣＴＩＯＵＳ　ＤＩＳＥＡＳＥ Ｖ８　Ｎ２, 200606, Ｐ９５-１０１ *
JPN5010008992; ＲＡＮＤＨＡＷＡ　Ｐ．: ＡＮＴＩＭＩＣＲＯＢＩＡＬ　ＡＧＥＮＴＳ　ＡＮＤ　ＣＨＥＭＯＴＨＥＲＡＰＹ Ｖ５０　Ｎ４, 200604, Ｐ１５６４-１５６６ *
JPN5010008994; ＥＲＩＫ　ＤＥ　ＣＬＥＲＣＱ: ＡＮＴＩＶＩＲＡＬ　ＲＥＳＥＡＲＣＨ Ｖ７５　Ｎ１, 20070417, Ｐ１-１３, ＥＬＳＥＶＩＥＲ　ＳＣＩＥＮＣＥ　ＢＶ *
JPN5010009002; ＪＡＣＯＢＳＯＮ　Ｍ．　Ａ．: ＤＲＵＧ　ＴＨＥＲＡＰＹ Ｖ３３７　Ｎ２, 19970710, Ｐ１０５-１１４ *
JPN6013023561; Ｂｏｎｅ　Ｍａｒｒｏｗ　Ｔｒａｎｓｐｌａｎｔａｔｉｏｎ ２６, 2000, ３４７-３５０ *
JPN7013001837; Ｐｒｅｄｉａｔｒ　Ｔｒａｎｓｐｌａｎｔａｔｉｏｎ １０, 2006, １２１-１２７ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519570A (ja) * 2016-06-28 2019-07-11 キメリックス インコーポレイテッド ブリンシドフォビルの製剤
JP2021143178A (ja) * 2016-06-28 2021-09-24 キメリックス インコーポレイテッド ブリンシドフォビルの製剤
JP7221485B2 (ja) 2016-06-28 2023-02-14 エマージェント バイオディフェンス オペレーションズ ランシング エルエルシー ブリンシドフォビルの製剤
JP2023033538A (ja) * 2016-06-28 2023-03-10 エマージェント バイオディフェンス オペレーションズ ランシング エルエルシー ブリンシドフォビルの製剤
JP7407984B2 (ja) 2016-06-28 2024-01-04 エマージェント バイオディフェンス オペレーションズ ランシング エルエルシー ブリンシドフォビルの製剤
US12485131B2 (en) 2016-06-28 2025-12-02 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir

Also Published As

Publication number Publication date
ES2609095T3 (es) 2017-04-18
AU2008246195B2 (en) 2014-06-05
AU2008246195A1 (en) 2008-11-06
US20120010170A1 (en) 2012-01-12
US20160303147A1 (en) 2016-10-20
CN102702260A (zh) 2012-10-03
JP2015063538A (ja) 2015-04-09
MX2009011573A (es) 2010-01-20
CA2685285A1 (en) 2008-11-06
CN101678122A (zh) 2010-03-24
EP2155257A1 (en) 2010-02-24
WO2008133966A1 (en) 2008-11-06
EP2155257B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
JP2015063538A (ja) ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
JP5963894B2 (ja) ホスホネート化合物
EP0837630B1 (en) Prodrugs of pharmaceuticals with improved bioavailability
US8193167B2 (en) Pharmacologically active agents containing esterified phosphonates and methods for use thereof
JPH10508858A (ja) 改良抗ウイルス性プロドラッグ
US20110263536A1 (en) Methods of Treating Orthopox Virus Infections and Associated Diseases
EP1914237B1 (en) Phosphonate ester antiviral compounds
HK1114858B (en) Phosphonate ester antiviral compounds
HK1114858A (en) Phosphonate ester antiviral compounds
ZA200204194B (en) Phosphonate compounds.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130819

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141119

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20141217